Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.44 USD
+1.12 (4.10%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $28.36 -0.08 (-0.28%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 28.44 +1.12(4.10%)
Will RARE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
Other News for RARE
Tactical Resources Announces Execution Of Amendment To Business Combination Agreement With Plum Acquisition Corp. III
Ultragenyx (RARE) Completes Enrollment for Phase 3 Study on Angelman Syndrome Treatment
Ultragenyx Pharmaceutical Inc (RARE) Advances Phase 3 Aspire Study for Angelman Syndrome ...
Ultragenyx completes enrollment of GTX-102 trial
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of ...